Workflow
Phibro(PAHC)
icon
Search documents
Phibro(PAHC) - 2022 Q3 - Earnings Call Transcript
2022-05-08 11:44
Financial Performance and Key Metrics - Consolidated net sales for Q3 2022 were $239.6 million, reflecting a 13% increase year-over-year, driven by improvements across all business segments [21] - GAAP-based net income and diluted earnings per share increased by 45% and 47% respectively compared to the same quarter last year [21] - Adjusted net income and adjusted diluted earnings per share declined by 4% and 3% respectively due to increased employee-related and technology-related costs [24] Business Segment Performance - The Animal Health segment posted net sales of $148.6 million, an 11% increase year-over-year, with notable growth in MFAs, nutritional specialties, and vaccines [25] - Mineral Nutrition segment net sales were $69 million, a 19% increase year-over-year, driven by higher average selling prices of trace minerals [28] - Performance Products segment net sales were $22 million, reflecting a 15% improvement over the same quarter last year [30] Market Data and Key Metrics - Sales in Europe, Middle East, and Africa represented 13% of consolidated net sales, while Asia Pacific accounted for 7% [14] - The company has limited indirect sales to Russia, which has resulted in some lost sales in Q3 and going forward [37] Company Strategy and Industry Competition - The company plans to continue taking price increases to combat historic levels of inflation and improve profitability [15][17] - An acquisition in Brazil aims to replicate success in the U.S. ethanol industry, providing products and services for ethanol production and its co-products [9] Management's Comments on Operating Environment and Future Outlook - Management highlighted macroeconomic headwinds, including the Russian conflict and lingering COVID-19 impacts, which could adversely affect business [11] - Revised full-year sales guidance is set at $930 million to $950 million, reflecting a projected year-over-year increase of 12% to 14% [18][39] Other Important Information - The company plans to publish its inaugural Economic, Social, and Governance (ESG) report shortly [41] - Free cash flow for the 12-month period ending March 31, 2022, was $1 million, with total debt of $417 million resulting in a gross leverage ratio of 3.9 times [32] Q&A Session Summary Question: Sales growth of Rejensa and outlook for the year - Sales for Rejensa are expected to double in fiscal year '22 compared to fiscal year '21, with continued strong performance anticipated [44] Question: Effects on U.S. beef and dairy franchises - The drought in the U.S. is not directly affecting the company, but there may be indirect effects on sales to the beef industry in other markets [45]
Phibro(PAHC) - 2022 Q3 - Quarterly Report
2022-05-04 20:18
[PART I—FINANCIAL INFORMATION](index=3&type=section&id=PART%20I%E2%80%94FINANCIAL%20INFORMATION) This section provides the unaudited consolidated financial statements and management's discussion and analysis for Phibro Animal Health Corporation [Item 1. Financial Statements](index=3&type=section&id=Item%201.%20Financial%20Statements) This section presents Phibro Animal Health Corporation's unaudited consolidated financial statements, including statements of operations, balance sheets, and cash flows, for the specified periods [Consolidated Statements of Operations](index=3&type=section&id=Consolidated%20Statements%20of%20Operations) This section details the company's consolidated statements of operations, highlighting net sales, gross profit, operating income, net income, and diluted EPS Consolidated Statements of Operations Highlights (in thousands, except per share amounts) | Metric | Three Months Ended Mar 31, 2022 | Three Months Ended Mar 31, 2021 | Nine Months Ended Mar 31, 2022 | Nine Months Ended Mar 31, 2021 | | :--- | :--- | :--- | :--- | :--- | | **Net sales** | $239,619 | $211,729 | $686,996 | $613,072 | | **Gross profit** | $71,626 | $69,165 | $206,976 | $201,549 | | **Operating income** | $19,194 | $20,132 | $56,100 | $55,710 | | **Net income** | $17,689 | $12,161 | $41,688 | $37,264 | | **Diluted EPS** | $0.44 | $0.30 | $1.03 | $0.92 | [Consolidated Balance Sheets](index=5&type=section&id=Consolidated%20Balance%20Sheets) This section presents the company's consolidated balance sheets, detailing assets, liabilities, and stockholders' equity at specific periods Consolidated Balance Sheet Highlights (in thousands) | Metric | March 31, 2022 | June 30, 2021 | | :--- | :--- | :--- | | **Total current assets** | $546,477 | $498,909 | | **Total assets** | $916,181 | $841,325 | | **Total current liabilities** | $187,102 | $164,116 | | **Total liabilities** | $649,236 | $602,796 | | **Total stockholders' equity** | $266,945 | $238,529 | [Consolidated Statements of Cash Flows](index=6&type=section&id=Consolidated%20Statements%20of%20Cash%20Flows) This section outlines the company's consolidated cash flow activities, including operating, investing, and financing cash flows Consolidated Cash Flow Highlights (Nine Months Ended Mar 31, in thousands) | Metric | 2022 | 2021 | | :--- | :--- | :--- | | **Net cash provided by operating activities** | $30,075 | $45,236 | | **Net cash used by investing activities** | ($13,042) | ($11,390) | | **Net cash provided (used) by financing activities** | $3,954 | ($21,632) | | **Net increase in cash and cash equivalents** | $20,536 | $12,760 | [Notes to Consolidated Financial Statements](index=8&type=section&id=Notes%20to%20Consolidated%20Financial%20Statements) This section provides detailed notes to the consolidated financial statements, including segment information, acquisitions, and contingencies - The company operates in three business segments: **Animal Health**, **Mineral Nutrition**, and **Performance Products**[33](index=33&type=chunk) Net Sales by Product Type (in thousands) | Product Type | Three Months 2022 | Three Months 2021 | Nine Months 2022 | Nine Months 2021 | | :--- | :--- | :--- | :--- | :--- | | **Animal Health** | $148,589 | $134,380 | $440,520 | $398,987 | | **Mineral Nutrition** | $69,033 | $58,153 | $190,120 | $163,750 | | **Performance Products** | $21,997 | $19,196 | $56,356 | $50,335 | | **Total** | **$239,619** | **$211,729** | **$686,996** | **$613,072** | Net Sales by Region (in thousands) | Region | Three Months 2022 | Three Months 2021 | Nine Months 2022 | Nine Months 2021 | | :--- | :--- | :--- | :--- | :--- | | **United States** | $146,820 | $129,370 | $412,284 | $370,446 | | **Latin America and Canada** | $45,048 | $37,386 | $135,722 | $115,808 | | **Europe, Middle East and Africa** | $29,931 | $27,802 | $90,889 | $84,959 | | **Asia Pacific** | $17,820 | $17,171 | $48,101 | $41,859 | | **Total** | **$239,619** | **$211,729** | **$686,996** | **$613,072** | - In February 2022, the company acquired a business for **$13.7 million** that develops processing aids for the ethanol fermentation industry, included in the MFAs and other product category under the Animal Health segment[43](index=43&type=chunk)[44](index=44&type=chunk) - The company is involved in an environmental investigation by the EPA regarding groundwater contamination at the Omega Chemical Corporation Superfund Site, with potential liability uncertain[57](index=57&type=chunk)[58](index=58&type=chunk) [Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations](index=24&type=section&id=Item%202.%20Management%27s%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations) Management analyzes the company's financial condition and operational results, discussing sales growth, segment performance, and the impact of external factors like geopolitical events and regulatory reviews [Overview and Key Trends](index=24&type=section&id=Overview%20and%20Key%20Trends) This section provides an overview of key trends and external factors impacting the company, including geopolitical conflicts, regulatory reviews, and the ongoing pandemic - Sales to Russia and Ukraine represent approximately **1%** of annual consolidated net sales, and the company intends to continue providing medicines and vaccines to existing customers in Russia[84](index=84&type=chunk)[85](index=85&type=chunk) - The FDA is reviewing the safety of carbadox (Mecadox), and its potential withdrawal could adversely affect financial results[91](index=91&type=chunk)[93](index=93&type=chunk) - Sales of Mecadox totaled **$20 million** for the twelve months ended March 31, 2022[93](index=93&type=chunk) - The company continues to navigate the COVID-19 pandemic, maintaining operations and employee safety despite some cost increases from supply chain disruptions[87](index=87&type=chunk)[88](index=88&type=chunk)[89](index=89&type=chunk) [Results of Operations](index=27&type=section&id=Results%20of%20Operations) This section details the company's operational performance, including net sales, gross profit, operating income, and net income, with segment-level analysis Q3 FY2022 vs Q3 FY2021 Performance (in thousands) | Metric | Three Months Ended Mar 31, 2022 | Three Months Ended Mar 31, 2021 | Change $ | Change % | | :--- | :--- | :--- | :--- | :--- | | **Net Sales** | $239,619 | $211,729 | $27,890 | 13% | | **Gross Profit** | $71,626 | $69,165 | $2,461 | 4% | | **Operating Income** | $19,194 | $20,132 | ($938) | (5)% | | **Net Income** | $17,689 | $12,161 | $5,528 | 45% | - For the three months ended March 31, 2022, net sales increased **13%** year-over-year, driven by growth in Animal Health (**+11%**), Mineral Nutrition (**+19%**), and Performance Products (**+15%**)[99](index=99&type=chunk)[100](index=100&type=chunk)[101](index=101&type=chunk)[102](index=102&type=chunk) - For the nine months ended March 31, 2022, net sales increased **12%** year-over-year, driven by growth in Animal Health (**+10%**), Mineral Nutrition (**+16%**), and Performance Products (**+12%**)[112](index=112&type=chunk)[113](index=113&type=chunk)[114](index=114&type=chunk)[115](index=115&type=chunk) - Gross margin for Q3 FY2022 decreased to **29.9%** from **32.7%** in the prior year, primarily due to increased raw material and logistics costs[103](index=103&type=chunk)[104](index=104&type=chunk) - Adjusted EBITDA for Q3 FY2022 remained flat at **$28.0 million**, with an increase in Mineral Nutrition Adjusted EBITDA offset by a decrease in Animal Health Adjusted EBITDA[111](index=111&type=chunk) [Liquidity and Capital Resources](index=33&type=section&id=Liquidity%20and%20Capital%20Resources) This section discusses the company's liquidity position, cash flow from operating, investing, and financing activities, and available capital resources - Net cash provided by operating activities for the nine months ended March 31, 2022, was **$30.1 million**, a decrease from **$45.2 million** in the prior year, primarily due to increased use of cash for inventory and receivables[125](index=125&type=chunk)[127](index=127&type=chunk) - Investing activities used **$13.0 million**, including **$25.2 million** for capital expenditures and **$10.8 million** for a business acquisition, partially offset by a **$20.9 million** net reduction in short-term investments[128](index=128&type=chunk) - As of March 31, 2022, the company held **$92.8 million** in cash, cash equivalents, and short-term investments, with **$123.3 million** available under its 2021 Revolver facility[131](index=131&type=chunk)[132](index=132&type=chunk) - The Board of Directors declared a quarterly cash dividend of **$0.12 per share**, payable on June 22, 2022[133](index=133&type=chunk) [Item 3. Quantitative and Qualitative Disclosures About Market Risk](index=38&type=section&id=Item%203.%20Quantitative%20and%20Qualitative%20Disclosures%20About%20Market%20Risk) The company reports no material changes in market risk exposures, including interest rates and foreign currency, from prior disclosures, utilizing derivatives for hedging - There were no material changes in the Company's financial market risks related to interest rates and foreign currency exchange rates from the risks disclosed in the Annual Report[152](index=152&type=chunk) [Item 4. Controls and Procedures](index=38&type=section&id=Item%204.%20Controls%20and%20Procedures) Management confirms the effectiveness of disclosure controls and procedures, with no material changes to internal control over financial reporting during the quarter - Based on an evaluation as of March 31, 2022, the Chief Executive Officer and Chief Financial Officer concluded that the company's disclosure controls and procedures were effective[153](index=153&type=chunk) - There were no changes during the quarter ended March 31, 2022, that have materially affected, or are reasonably likely to materially affect, the company's internal control over financial reporting[154](index=154&type=chunk) [PART II—OTHER INFORMATION](index=39&type=section&id=PART%20II%E2%80%94OTHER%20INFORMATION) This section covers other required information, including legal proceedings, risk factors, and other miscellaneous disclosures [Item 1. Legal Proceedings](index=39&type=section&id=Item%201.%20Legal%20Proceedings) This section incorporates by reference information on legal proceedings from the commitments and contingencies notes in the financial statements - Refers to 'Notes to the Consolidated Financial Statements—Commitments and Contingencies' for information on legal proceedings[155](index=155&type=chunk) [Item 1A. Risk Factors](index=39&type=section&id=Item%201A.%20Risk%20Factors) The company reports no material changes to the risk factors previously disclosed in its Annual Report - There were no material changes in the Company's risk factors from the risks disclosed in the Annual Report[157](index=157&type=chunk) [Other Items (2, 3, 4, 5)](index=39&type=section&id=Other%20Items%20(2,%203,%204,%205)) This section confirms no unregistered sales of equity securities, no defaults on senior securities, and no other reportable information - Item 2 (Unregistered Sales of Equity Securities), Item 3 (Defaults Upon Senior Securities), and Item 5 (Other Information) are all reported as 'None'[158](index=158&type=chunk)[159](index=159&type=chunk)[161](index=161&type=chunk) - Item 4 (Mine Safety Disclosures) is reported as 'Not applicable'[160](index=160&type=chunk)
Phibro(PAHC) - 2022 Q2 - Earnings Call Presentation
2022-02-11 17:59
Phibro Animal Health Corporation Financial Results Fiscal Year 2022 Second Quarter Ended December 31, 2021 Webcast and Conference Call February 10, 2022 U.S. toll-free +1-888-330-2022 International toll +1-365-977-0051 Conference ID: 3927884 February 10, 2022 Important Information Cautionary Statement Regarding Forward-Looking Statements This communication contains forward-looking statements that are subject to risks and uncertainties, including with respect to future debt and leverage levels. All statement ...
Phibro(PAHC) - 2022 Q2 - Earnings Call Transcript
2022-02-10 18:21
Phibro Animal Health Corporation (NASDAQ:PAHC) Q2 2022 Earnings Conference Call February 10, 2022 9:00 AM ET Company Participants Damian Finio - Chief Financial Officer Jack Bendheim - Chairman, President & Chief Executive Officer Daniel Bendheim - Director & Executive Vice President of Corporate Strategy Conference Call Participants Erin Wright - Morgan Stanley Michael Ryskin - Bank of America Operator Good morning. My name is Shantel and I'll be your conference operator today. At this time, I would like t ...
Phibro(PAHC) - 2022 Q2 - Quarterly Report
2022-02-09 21:11
[PART I—FINANCIAL INFORMATION](index=3&type=section&id=PART%20I%E2%80%94FINANCIAL%20INFORMATION) [Financial Statements (unaudited)](index=4&type=section&id=Item%201.%20Financial%20Statements%20(unaudited)) The company reported increased net sales for both the quarter and six-month period, with quarterly net income up significantly, while total assets and operating cash flow saw modest changes Consolidated Statements of Operations Net sales increased for both the three and six-month periods, with quarterly net income growing significantly, while six-month net income experienced a slight decrease Consolidated Statements of Operations Highlights (in thousands, except per share amounts) | For the Periods Ended December 31 | Three Months 2021 | Three Months 2020 | Six Months 2021 | Six Months 2020 | | :--- | :--- | :--- | :--- | :--- | | **Net sales** | $232,712 | $206,149 | $447,377 | $401,343 | | **Gross profit** | $70,672 | $68,265 | $135,350 | $132,384 | | **Operating income** | $22,294 | $19,890 | $36,906 | $35,578 | | **Net income** | $17,465 | $12,801 | $23,999 | $25,103 | | **Diluted EPS** | $0.43 | $0.32 | $0.59 | $0.62 | Consolidated Balance Sheets Total assets and liabilities increased slightly as of December 31, 2021, driven by higher inventories and increased borrowings under the revolving credit facility Consolidated Balance Sheet Highlights (in thousands) | As of | December 31, 2021 | June 30, 2021 | | :--- | :--- | :--- | | **Total current assets** | $508,610 | $498,909 | | **Total assets** | $848,958 | $841,325 | | **Total current liabilities** | $166,628 | $164,116 | | **Total liabilities** | $609,664 | $602,796 | | **Total stockholders' equity** | $239,294 | $238,529 | Consolidated Statements of Cash Flows Net cash provided by operating activities decreased due to higher inventories, while investing and financing activities resulted in net cash outflows, including dividend payments Six Months Ended Dec 31 - Cash Flow Summary (in thousands) | Activity | 2021 | 2020 | | :--- | :--- | :--- | | **Net cash provided by operating activities** | $23,943 | $28,611 | | **Net cash used by investing activities** | ($3,098) | ($21,259) | | **Net cash used by financing activities** | ($6,311) | ($10,084) | | **Net increase (decrease) in cash** | $13,173 | ($1,809) | Notes to Consolidated Financial Statements Notes provide details on business segments, revenue, debt, and contingencies, highlighting strong sales growth in Animal Health and Mineral Nutrition, alongside ongoing environmental and product safety issues Net Sales by Product Type (Six Months Ended Dec 31, in thousands) | Product Category | 2021 | 2020 | | :--- | :--- | :--- | | **Animal Health** | | | | MFAs and other | $175,482 | $160,280 | | Nutritional specialties | $73,327 | $68,994 | | Vaccines | $43,122 | $35,333 | | **Total Animal Health** | **$291,931** | **$264,607** | | **Mineral Nutrition** | $121,087 | $105,597 | | **Performance Products** | $34,359 | $31,139 | | **Total** | **$447,377** | **$401,343** | Net Sales by Region (Six Months Ended Dec 31, in thousands) | Region | 2021 | 2020 | | :--- | :--- | :--- | | United States | $265,464 | $241,077 | | Latin America and Canada | $90,674 | $78,421 | | Europe, Middle East and Africa | $60,961 | $57,157 | | Asia Pacific | $30,278 | $24,688 | | **Total** | **$447,377** | **$401,343** | - The company entered into an amended credit agreement in April 2021, which includes a **$300 million Term A Loan** and a **$250 million revolving credit facility**. As of December 31, 2021, the company was in compliance with all financial covenants[51](index=51&type=chunk)[52](index=52&type=chunk) - The company is named as a potentially responsible party (PRP) by the EPA for groundwater contamination at the Omega Chemical Superfund Site. The ultimate liability cannot be predicted with certainty at this time[61](index=61&type=chunk) [Management's Discussion and Analysis of Financial Condition and Results of Operations](index=24&type=section&id=Item%202.%20Management's%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations) Management attributes sales growth to Animal Health and Mineral Nutrition, despite gross margin pressure from rising costs, while actively managing COVID-19 impacts and FDA discussions on carbadox, maintaining strong liquidity Results of Operations Net sales increased for both the three and six-month periods, driven by Animal Health and Mineral Nutrition, though gross margin declined due to cost pressures, and six-month Adjusted EBITDA decreased Segment Net Sales (Three Months Ended Dec 31, in thousands) | Segment | 2021 | 2020 | Change | % Change | | :--- | :--- | :--- | :--- | :--- | | Animal Health | $150,927 | $136,238 | $14,689 | 11% | | Mineral Nutrition | $66,655 | $54,157 | $12,498 | 23% | | Performance Products | $15,130 | $15,754 | ($624) | (4)% | Segment Adjusted EBITDA (Three Months Ended Dec 31, in thousands) | Segment | 2021 | 2020 | Change | % Change | | :--- | :--- | :--- | :--- | :--- | | Animal Health | $33,696 | $33,349 | $347 | 1% | | Mineral Nutrition | $5,525 | $4,185 | $1,340 | 32% | | Performance Products | $1,324 | $2,266 | ($942) | (42)% | - Gross margin for Q2 FY22 decreased by **270 basis points** to **30.4%** compared to **33.1%** in the prior year, primarily due to increased raw material and logistics costs, and unfavorable product mix[100](index=100&type=chunk)[101](index=101&type=chunk) - The FDA is reviewing the safety of carbadox (Mecadox), which had sales of **$22 million** for the twelve months ended December 31, 2021. A potential withdrawal of approval would adversely affect financial results[90](index=90&type=chunk) Liquidity and Capital Resources The company maintains strong liquidity with substantial cash and available credit, sufficient to fund operations for the next twelve months, and declared a quarterly dividend Liquidity Measures (in thousands, except ratios) | As of | December 31, 2021 | June 30, 2021 | | :--- | :--- | :--- | | Cash, cash equivalents & short-term investments | $95,485 | $93,212 | | Working capital | $259,622 | $250,956 | | Ratio of current assets to current liabilities | 2.69:1 | 2.62:1 | - As of December 31, 2021, the company had **$107.0 million** in outstanding borrowings under its 2021 Revolver, with **$140.3 million** available for further borrowings[131](index=131&type=chunk) - The Board of Directors declared a quarterly cash dividend of **$0.12 per share**, payable on March 23, 2022[132](index=132&type=chunk) [Quantitative and Qualitative Disclosures About Market Risk](index=44&type=section&id=Item%203.%20Quantitative%20and%20Qualitative%20Disclosures%20About%20Market%20Risk) The company manages market risks from interest rates, foreign currency, and commodity prices using non-speculative derivative instruments, with no material changes since the last Annual Report - The company uses interest rate swaps to hedge exposure to fluctuating interest rates and foreign currency contracts to manage foreign currency risks[151](index=151&type=chunk) - There were no material changes in the company's financial market risks from those disclosed in the Annual Report on Form 10-K[152](index=152&type=chunk) [Controls and Procedures](index=45&type=section&id=Item%204.%20Controls%20and%20Procedures) Management concluded that disclosure controls and procedures were effective as of December 31, 2021, with no material changes to internal control over financial reporting during the quarter - The CEO and CFO concluded that the company's disclosure controls and procedures were effective as of December 31, 2021[153](index=153&type=chunk) - No changes occurred during the quarter that materially affected, or are reasonably likely to materially affect, the company's internal control over financial reporting[154](index=154&type=chunk) [PART II—OTHER INFORMATION](index=45&type=section&id=PART%20II%E2%80%94OTHER%20INFORMATION) [Legal Proceedings](index=45&type=section&id=Item%201.%20Legal%20Proceedings) The company is involved in various legal claims and lawsuits, not expected to have a material adverse effect, with environmental contingencies detailed in the financial statement notes - Information regarding legal proceedings is incorporated by reference from Note 7, "Commitments and Contingencies," in the financial statements[155](index=155&type=chunk)[65](index=65&type=chunk) [Risk Factors](index=45&type=section&id=Item%201A.%20Risk%20Factors) No material changes to the company's risk factors have occurred since the Annual Report on Form 10-K, advising investors to consider previously disclosed risks - There were no material changes in the Company's risk factors from the risks disclosed in the Annual Report[157](index=157&type=chunk) [Other Information](index=45&type=section&id=Item%205.%20Other%20Information) The company entered a severance agreement with CFO Damian Finio, providing a lump-sum payment and pro-rata bonus upon specific involuntary or voluntary termination conditions - The company entered into a severance protection letter agreement with CFO Damian Finio on February 7, 2022[161](index=161&type=chunk) - The agreement provides for a severance payment of **100% of base salary** plus a pro-rata bonus upon involuntary termination without 'Cause' or resignation for 'Good Reason'[161](index=161&type=chunk)
Phibro(PAHC) - 2022 Q1 - Earnings Call Transcript
2021-11-06 03:51
Phibro Animal Health Corporation (NASDAQ:PAHC) Q3 2022 Earnings Conference Call November 3, 2021 9:00 AM ET Company Participants Damian Finio - CFO Jack Bendheim - Chairman, President and CEO Daniel Bendheim - Director and EVP, Corporate Strategy Conference Call Participants Erin Wright - Morgan Stanley Michael Ryskin - Bank of America David Westenberg - Guggenheim Securities Operator Good morning. My name is Shantel, and I will be your conference operator today. At this time, I would like to welcome everyo ...
Phibro(PAHC) - 2022 Q1 - Quarterly Report
2021-11-02 20:31
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36410 Phibro Animal Health Corporation (Exact name of registrant as specified in its charter) Delaware 13 ...
Phibro(PAHC) - 2021 Q4 - Earnings Call Transcript
2021-08-26 15:52
Phibro Animal Health Corporation (NASDAQ:PAHC) Q4 2021 Earnings Conference Call August 26, 2021 9:00 AM ET Company Participants Damian Finio - CFO Jack Bendheim - Chairman, President and CEO Donny Bendheim - Director and EVP, Corporate Strategy Conference Call Participants Katie Tryhane - Credit Suisse Michael Ryskin - Bank of America Operator Thank you for standing by and welcome to the Phibro Animal Health Corporation Q4 2020 (sic) [2021] Conference Call. At this time, all participants are in a listen-onl ...
Phibro(PAHC) - 2021 Q4 - Annual Report
2021-08-25 20:32
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended June 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36410 | Class A Common Stock, $0.0001 | | | | --- | --- | --- | | Title of each class par value per share | Trading Sy ...
Phibro(PAHC) - 2021 Q3 - Earnings Call Transcript
2021-05-09 19:31
Phibro Animal Health Corporation (NASDAQ:PAHC) Q3 2021 Earnings Conference Call May 7, 2021 9:00 AM ET Company Participants Damian Finio - Chief Financial Officer Jack Bendheim - Chairman, President & Chief Executive Officer Donny Bendheim - Director & Executive Vice President of Corporate Strategy Conference Call Participants David Westenberg - Guggenheim Securities Erin Wright - Credit Suisse Michael Ryskin - Bank of America Kevin Kedra - G. Research Operator Good day and thank you for standing by. Welco ...